InsiderTradr

Pacific Edge Limited (PEB.NZ)

NZSE · NZD · Healthcare · Diagnostics & Research

NZ$0.23 (+0.00%) as of

Key statistics

Market cap
285.63M
Forward P/E
-19.10
EPS (TTM)
-0.0400
Dividend yield
0.00%
52-week range
0.1370 – 0.3400
Beta
0.84
Revenue (TTM)
13.01M
Profit margin
-274.96%
Analyst target
NZ$0.20
Volume
1.46M

About Pacific Edge Limited

Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the stratification and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up in microhematuria patients; Cxbladder Detect, which improve practice workflow and efficiency in urological care; Cxbladder Triage Plus, a non-invasive surveillance alternative that can reduce the burden of repeated cystoscopy in patients; and Cxbladder Monitor, a non-invasive surveillance alternative that reduces the burden of repeated cystoscopy in patients with a recurrent non-muscle invasive bladder cancer. In addition, the company is developing products for bladder, gastric, colorectal and endometrial cancers, and melanoma. Pacific Edge Limited was incorporated in 2001 and is headquartered in Dunedin, New Zealand.

Sector
Healthcare
Industry
Diagnostics & Research
Headquarters
Dunedin, New Zealand

pacificedgedx.com

Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.

Related stocks